中枢神经系统良性肿瘤的正电子加速器断段放射治疗：文献系统综述。
Hypofractionated Proton Therapy for Benign Tumors of the Central Nervous System: A Systematic Review of the Literature.
发表日期：2023 Sep 06
作者：
Gaia Piperno, Annamaria Ferrari, Stefania Volpe, Federica Cattani, Mattia Zaffaroni, Stefania Comi, Floriana Pansini, Luca Bergamaschi, Giovanni Carlo Mazzola, Francesco Ceci, Marzia Colandrea, Giuseppe Petralia, Roberto Orecchia, Barbara Alicja Jereczek-Fossa, Daniela Alterio
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
本研究的目的是报告对中枢神经系统（CNS）良性病变患者接受低剂量前列腺素（hypoF PT）治疗的文献系统综述结果。研究方法符合PRISMA推荐的要求。在2022年9月，我们检索了PubMed、EMBASE和Scopus数据库。选择了12篇文章，其中包括接受治疗的颅底脑膜瘤（6篇文章）、前庭神经瘤（3篇文章）和垂体腺瘤（3篇文章）患者。临床结果通过放射影像和临床参数进行评估。长期毒性在所有系列中均有报道，颅底脑膜瘤患者的发生率为2%至7%，前庭神经瘤患者为1%至9%。低剂量前列腺素治疗对于选择的CNS良性肿瘤是安全有效的。需要进一步进行剂量测量和临床比较，以更好地细化患者的选择标准。版权所有 © 2023 Elsevier B.V. 发表。
Aim of the present analysis was to report results of a systematic review of the literature in the setting of patients treated with hypoF PT for benign lesions of the central nervous system (CNS).The methodology complied with the PRISMA recommendations. PubMed, EMBASE and Scopus databases were interrogated in September 2022.Twelve papers have been selected including patients treated for base of the skull meningiomas (6 papers), vestibular schwannoma (3 papers) and pituitary adenomas (3 papers). Clinical outcomes were evaluated with both radiologic images and clinical parameters. Long-term toxicity was reported in all but one series with an incidence ranging from 2 to 7% in patients treated for base of skull meningioma and 1-9% for schwannoma.HypoF PT is a safe and effective treatment in selected benign tumors of the CNS. Further dosimetric and clinical comparisons are required to better refine the patients' selection criteria.Copyright © 2023. Published by Elsevier B.V.